Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CTX-1 + Nutlin-3a|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CTX-1||CTX1||MDM4 inhibitor 8||CTX-1 binds to and inhibits Mdm4 (MdmX), which disrupts the interaction between Tp53 and Mdm4, leading to stabilization of Tp53 and potentially leading to increased tumor cell death (PMID: 26883273).|
|Nutlin-3a||Nutlin|Nutlin-3||MDM2 Inhibitor 22||Nutlin-3a is an MDM2 inhibitor that activates p53, potentially resulting in induction of apoptosis and senescence in tumor cells (PMID: 18451145, PMID: 32653500).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 wild-type||acute myeloid leukemia||sensitive||CTX-1 + Nutlin-3a||Preclinical||Actionable||In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).||26883273|
|TP53 wild-type||Advanced Solid Tumor||sensitive||CTX-1 + Nutlin-3a||Preclinical||Actionable||In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).||26883273|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|